Stay updated on Pembrolizumab vs Standard Therapy in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in Esophageal Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Therapy in Esophageal Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page’s footer “Revision” label was updated from v3.5.2 to v3.5.3, indicating a site or system version change rather than an update to the study record itself.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision updated to v3.5.2, replacing the previous v3.5.0.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedCarcinoma of esophagus was added to the conditions list. A Resources section linking to the Genetic and Rare Diseases Information Center was added.SummaryDifference0.2%

- Check41 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check48 days agoChange DetectedSite revision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision: v3.4.2 is displayed, and the earlier notices about government funding, operating status, and related updates have been removed.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab vs Standard Therapy in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in Esophageal Cancer Clinical Trial page.